Introduction {#s1}
============

Evidence suggests that human semen quality has declined worldwide over the last several decades ([@c11]; [@c35]). In addition to adverse lifestyle factors such as cigarette smoking, alcohol and caffeine intake, obesity, stress, and high scrotal temperature ([@c20]; [@c43]; [@c46]), exposure to environmental contaminants is regarded as another important contributor ([@c34]; [@c48]). Per- and polyfluoroalkyl substances (PFASs) are a group of artificial chemicals now found as global environmental contaminants due to their extensive uses in industrial and consumer products ([@c29]). With increasing awareness that some common PFASs, such as perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS), are toxic, bioaccumulative, and biopersistent, with long half-lives in humans (e.g., 3.5 and 4.8 y for PFOA and PFOS, respectively) ([@c36]), governments and international organizations initiated the phaseout of these compounds in 2000 ([@c29]). These stricter regulations led to a geographical shift in the production and application of PFOS and PFOA to China ([@c56]) and the associated development of alternative compounds within Chinese industries, such as chlorinated polyfluorinated ether sulfonate (6:2 Cl-PFESA, trade name F-53B) as a replacement for PFOS ([@c42]; [@c55]). However, growing evidence suggests that these alternatives may be no safer than the legacy compounds they are meant to replace. For example, with an estimated half-life of 15.3 y in humans (longer than that of PFOA and PFOS), 6:2 Cl-PFESA is considered the most biopersistent PFAS reported to date ([@c47]) and the third most detected PFAS (next to PFOS and PFOA) in the serum of studied populations in China ([@c38]). Thus, this evidence implies increasing exposure to legacy and novel PFASs in the Chinese population, with the risk to semen quality also of great concern.

Indeed, toxicological studies have shown that exposure to PFASs at high doses (typically at the milligram per kilogram per day level) can impair male fecundity (e.g., decreased serum testosterone and epididymal sperm counts) in rodents ([@c27]; [@c54]; [@c62]). However, epidemiological evidence remains equivocal regarding the effects of PFASs on male reproductive function at environmentally relevant levels. To date, the associations between PFAS exposure and testicular function have been investigated in a number of different populations, including men from the general population ([@c22], [@c23]; [@c9]), male partners of pregnant women ([@c51]; [@c53]), subfertile couples attending infertility clinics ([@c17]; [@c41]; [@c50]), and occupational PFOA-exposed workers ([@c37]; [@c44]). Although such studies have indicated increasingly clear tendencies that higher exposure to PFASs (e.g., PFOS, PFOA) is associated with lower serum testosterone levels ([@c22], [@c23]; [@c31]; [@c41]; [@c66]), associations with other sex hormones, such as estradiol and luteinizing hormone, remain uncertain ([@c22], [@c23]; [@c31]; [@c41]; [@c44]; [@c51]; [@c66]). There is a lack of consistent results among the limited investigations concerning PFAS exposure and semen quality parameters ([@c4]). Although Joensen et al. ([@c22]) observed a significant tendency toward poorer sperm morphology with higher combined serum PFOS and PFOA levels in 105 healthy young men from a Danish population, this finding was not replicated in their later investigation when a larger sample size was included in another sampling year ([@c23]). Furthermore, Toft et al. ([@c53]) observed a higher percentage of motile sperm in the highest PFOA-exposed tertile, whereas Song et al. ([@c50]) found negative correlations between sperm motility and PFOA exposure.

The existing body of evidence is largely limited to the assessment of PFASs in serum or plasma. Given their strong binding affinities to serum albumin, PFASs can persist in human serum for years ([@c36]), making it a favorable matrix for determining the body burden of PFASs. However, measurement in serum does not necessarily reflect exposure to PFASs in a specific organ or tissue. Compared with PFAS levels in serum, those in semen may more likely represent the actual levels of PFASs entering the male reproductive system. It is possible that the potential effects on testicular function would be more clearly observed if seminal PFASs, rather than serum PFASs, were used as the exposure markers. As such, seminal PFAS levels are worth exploring as potential exposure markers for epidemiological studies. However, one must consider that using a more accurate measure of target organ exposure may introduce confounding that would not occur if a more remote measure of exposure was used ([@c57]).

Semen has been used for monitoring various contaminants ([@c14]) but has been rarely used for monitoring PFASs. Although trace levels of PFASs in semen were detected in earlier studies ([@c17]; [@c41]), the exploration of possible associations with semen quality was hampered by the poor limits of quantitation (LOQs; $0.4–3\text{ \ ng}/{mL}$), such that even dominant PFASs (e.g., PFOA and PFOS) could not be quantified. However, with the development of modern analytical instruments, the detection sensitivity of PFASs has increased by two to three orders of magnitude, thus allowing the quantification of trace levels of seminal PFASs. In fact, a recent study determined semen PFASs with LOQs reaching parts per trillion ([@c50]). Several PFASs have been detected in semen samples, with results indicating higher correlations (without adjustment for confounders) with semen quality than were detected with serum PFASs. However, this pilot study included only 103 men and two basic semen parameters (i.e., sperm concentration and motility). Research with a larger sample size, more comprehensive outcomes, and further confounders is necessary.

In the present investigation, we collected 664 matched-pair semen and serum samples from men attending an infertility clinic in Nanjing, China. Levels of PFASs, including legacy compounds and the novel alternative 6:2 Cl-PFESA, were quantified in both matrices. With the adjustment of potential covariates, the epidemiological associations with semen quality parameters were analyzed to test whether the effects of PFASs on semen quality could be better evaluated by levels in semen. To the best of our knowledge, this is the first study to investigate the patterns of PFASs between semen and serum. Such information is not only crucial for risk assessment but can also help elucidate the transfer of PFASs to the male reproductive system, which is important for understanding the risks and mechanisms of human reproductive toxicity.

Methods {#s2}
=======

Study Population and Sample Collection {#s2.1}
--------------------------------------

Male partners of couples were recruited at their first visit to the Reproductive Medical Center, Nanjing Jinling Hospital, Nanjing, China, regardless of their purpose for fertility assessment. The study population was heterogeneous, including men with fecundity issues as well as fertile men who were partners of women with female factor infertility. The criteria for subject selection were minimal; namely, being *a*) a Chinese citizen $\geq 18$ years of age and *b*) able to communicate in Chinese and complete the questionnaire. From June 2015 to July 2016, 1,630 eligible men were invited to join the investigation, with a total of 738 (45.3%) agreeing to participate. With the guidance of a trained nurse, each participant provided signed informed consent and filled out a face-to-face questionnaire; information collected included demographics (e.g., age, race, body weight, height, occupation), health condition \[e.g., reproductive (fathering) history and medical history\], and lifestyle factors (e.g., smoking and alcohol consumption status). Of the 738 participants, 74 were excluded: 59 reported severe reproductive tract diseases, including testicular cancer, azoospermia, cryptorchidism, grade II and III varicoceles, urogenital infections, testicular hydroceles, hypospadias, or sexually transmitted diseases; 6 were later diagnosed with azoospermia; 2 were taking medication to improve semen quality; 1 worked in a fluorochemical plant, indicating occupational exposure to PFASs; and 6 had inadequate semen volume left for PFAS measurement after routine semen analysis. Thus, the final sample size for this investigation was 664. The study was approved by the Human Subject Committee of Nanjing Jinling Hospital.

After a recommended abstinence period of 2 d, each participant provided a semen sample on site by masturbation into a sterile jar. Men with an abstinence period of $< 2\; d$ were asked to return later. Each participant was instructed to collect a complete ejaculate carefully and to record if any spillage occurred. Specimens were immediately analyzed for semen quality parameters, with the remaining aliquot kept at $- 80{^\circ}C$ for PFAS analysis.

On the same day as semen collection, each participant provided a venous blood sample. Serum was collected after centrifugation and stored at $- 80{^\circ}C$. Paired serum and semen samples were shipped to the laboratory in Beijing on dry ice and stored at $- 80{^\circ}C$ until PFAS analysis.

PFAS Analysis {#s2.2}
-------------

A total of 16 target PFASs, including perfluorobutanoate (PFBA), perfluoropentanoate (PFPeA), perfluorohexanoate (PFHxA), perfluoroheptanoate (PFHpA), PFOA, perfluorononanoate (PFNA), perfluorodecanoate (PFDA), perfluoroundecanoate (PFUnDA), perfluorododecanoate (PFDoDA), perfluorotridecanoate (PFTriDA), perfluorotetradecanoate (PFTeDA), perfluorobutane sulfonate (PFBS), perfluorohexane sulfonate (PFHxS), PFOS, and 6:2 and 8:2 Cl-PFESAs, were measured following our previously published methods ([@c38]). For additional information see "Standards and reagents," "Sample extraction," and "Instrument analysis" in the Supplemental Material and Table S1. Briefly, serum and semen samples were extracted using ion-pair extraction. The extracts were analyzed using an Acquity UPLC™ coupled to a Xevo™ TQ-S triple quadrupole mass spectrometer (Waters). Procedural blanks, matrix recovery tests, certified reference materials, and additional isotope-labeled injection standards were applied to ensure accurate quantification of PFASs. All labware and solvents were prescreened to reduce possible contamination. Spike recoveries ($n = 5$) were validated by spiking mixed native standards (final concentration 0.1 and $1\text{ \ ng}/{mL}$) into a blank matrix (commercial fetal bovine serum or pooled semen from three healthy volunteers) and subjected to the same extraction. The recoveries of PFASs in the serum and semen samples ranged from 84% to 112% (see Table S2). The LOQs were established based on three criteria: *a*) concentration resulting in a signal-to-noise ratio of 10 in different matrices, *b*) lowest concentration of standard in the calibration curve with measured concentrations within $\pm 20\%$ of its theoretical value, and *c*) concentration factor. The LOQs are shown in Table S2, with values ranging from $0.01–0.20\text{ \ ng}/{mL}$ for serum and $0.002–0.10\text{ \ ng}/{mL}$ for semen. In daily operation, one extraction blank and one quality control sample (SRM1957; NIST) were injected in every 20 samples to ensure accurate quantification of PFASs. An 11-point calibration curve was verified and exhibited excellent linearity in the range of $0.01–20\text{ \ ng}/{mL}$ ($R^{2} > 0.99$). Instrumental drift was checked by injecting a $0.1\text{-ng}/{mL}$ standard in every 10 samples. A new calibration curve was reconstructed if the deviation was greater than $\pm 20\%$ from its theoretical concentration. No instrumental drift was observed during any batch.

Semen Analysis {#s2.3}
--------------

Semen samples were analyzed after liquefaction at 37°C. Semen volume was calculated from sample weight, assuming the density of semen to be $1\; g/{mL}$. Sperm concentration and motility were determined by the CFT-9201 computer-aided sperm analysis system (CASA; Jiangsu Rich Life Science Instrument Co., Ltd.). The analyses were achieved within 60 min of ejaculation to minimize the effect of ejaculation-to-analysis delay on sperm motility. Total sperm count was calculated by multiplying sperm concentration with semen volume. Sperm kinematic parameters were measured along with sperm motility by CASA. Kinematic parameters included curvilinear velocity (VCL), straight-line velocity (VSL), linearity ($\text{LIN} = \text{VSL}/\text{VCL} \times 100\%$), average path velocity (VAP), amplitude of lateral head displacement (ALH), and beat cross frequency (BCF). These parameters describe different aspects of sperm movement; VSL, VAP, and LIN are indicators of sperm progression, whereas VCL, ALH, and BCF are indicators of sperm vigor. Because these parameters were strongly correlated with each other, only VSL and VCL were further analyzed as indicators of sperm progression and vigor, respectively. VCL and VSL were selected over other parameters because they are the most well-known kinematic parameters and are not heavily dependent on the type of CASA instrument ([@c58]). Sperm morphology slides (at least 200 spermatozoa per slide) were fixed and Shorr-stained in duplicate and were evaluated according to the World Health Organization (WHO) criteria. Average percentage of normal morphology was reported if the difference between the two replicates was acceptable; when it was not, the assessment was repeated with two new aliquots of the semen sample. The sperm chromatin stability assay (SCSA) was conducted using a FACSCalibur Flow Cytometer (Becton Dickinson). Parameters, including DNA fragmentation index (DFI; percentage of sperm with damaged DNA) and high DNA stainability (HDS; percentage of sperm with immature chromatin) were then quantified ([@c15]). Three trained technicians without any knowledge of the study subjects completed the routine semen analysis, morphological assessment, and SCSA assay, respectively. All three technicians had participated in a continuous quality control program under the supervision of the Quality Control Committee of Nanjing Jinling Hospital. The program was conducted to ensure good agreement in the assessment of sperm concentration using the CASA system against a hemocytometer. In addition, two known concentrations of latex beads (Hamilton-Thorne Inc.) were used to validate the accuracy of the CASA counts. In daily operation, aliquots of preserved semen samples, video recordings, and stained semen slides were analyzed at intervals for internal quality control of sperm concentration, motility, and morphology, respectively.

Statistical Analysis {#s2.4}
--------------------

Basic descriptive statistics were assessed for the distributions of subject demographics, semen parameters, and PFAS concentrations in serum and semen. Several PFASs with extremely low detection frequencies (i.e., PFHpA, PFTeDA, and PFBS, detection rate 2.7--14%) were excluded from further exploration. For all other PFASs, censored likelihood multiple imputation ([@c8]) was used to impute concentrations below the LOQ. Concentrations lower than the LOQ were imputed according to available data for the subject's age and linear and quadratic terms of body mass index (BMI and $\text{BMI}^{2}$). These variables were selected over other variables because they significantly predicted PFAS levels with correlations $\geq 0.05$. Pearson's correlations were used to test the within-matrix and between-matrix correlations of PFAS concentrations. The concentration ratio (semen vs. serum) was calculated to indicate the extent of PFASs entering the male reproductive system from the whole body. It is worth noting that the multiple imputation method makes assumptions about the distribution of the unobserved values, and the potential influence of deviations from these assumptions will increase with the proportion of imputed sample. In that case, relevant results for the PFASs with large proportions below the LOQ, such as PFDoDA, PFTriDA, PFHxS, and 8:2 Cl-PFESA, may be biased, and hence were only exploratory.

The associations of semen quality parameters with each PFAS in serum or semen were evaluated using multivariable linear regression analysis. PFAS concentrations were first modeled as continuous variables (ln-transformed); only target PFASs with detection frequencies greater than 80% were included in the analysis. Sensitivity analysis was then conducted by including both semen and serum PFAS concentrations into the model to describe how estimates vary compared with the serum-only or semen-only estimates. To explore the nonlinear relationships, PFASs were also divided into quartiles and entered into the model as categorical variables using three dichotomous indicator terms, with the lowest quartile used as the reference category. *p*-Values for linear trends were then derived by fitting the median concentrations of PFASs in each quartile and adding them to the model as continuous variables. To achieve normality of distribution of the residuals, dependent variables were either ln-transformed (semen volume, DFI, and HDS) or cubic-root transformed (sperm concentration and total sperm count). Sperm motility, VCL, VSL, and morphology exhibited close to normal distribution, and hence were included in the regressions untransformed. Residual regression plots were visually assessed to confirm normality assumptions. Subjects reporting spillage during semen collection ($n = 21$) were excluded from the models for semen volume, sperm concentration, and total sperm count. In the models of associations, we adjusted *a priori* for age (years; continuous), BMI and $\text{BMI}^{2}$ (kilograms per meter squared; continuous), smoking (none, $< 1$, 1--9, 10--19, and $\geq 20\text{ \ cigarettes}/d$ during the last 3 months; categorical), alcohol consumption ($\geq 1$ alcoholic beverage/week during the previous 3 months; dichotomous), and abstinence time (days; continuous) because these are known to influence semen quality ([@c12]; [@c21]; [@c25]; [@c26]; [@c40]). Occupational hazards (extreme heat, heavy exertion, chemical exposure, any of these or not; dichotomous) and medical history (self-reported disease vs. not reported; dichotomous) were also evaluated as possible confounders, but neither met the confounder criteria, whose inclusion would cause PFAS estimates to change by $\geq 10\%$ ([@c18]). To reduce the overall testing error rate, we used false discovery rate (FDR)-adjusted *p*-values for multiple comparisons. All *p*-values in models were adjusted using the spreadsheet software developed by Pike ([@c39]). An FDR-adjusted $p < 0.05$ was considered statistically significant in all models. We used R statistical software (version 3.1.1; R Development Core Team) for the censored likelihood multiple imputation \[chmi package ([@c8])\]. All other statistical analyses were performed using IBM PASW statistics (version 25.0; SPSS Inc.).

Results {#s3}
=======

Population Characteristics {#s3.1}
--------------------------

The demographics and semen parameters of the 664 eligible men are displayed in [Table 1](#t1){ref-type="table"}. The mean $\pm \text{standard\  \ deviation}$ (SD) of the age and BMI of participants was $29.4 \pm 5.4\; y$ and $23.9 \pm 3.1{\,{kg}/m}^{2}$, respectively. Mean abstinence time before semen collection was $4.8 \pm 2.2\; d$. Among the participants, 54% were nonsmokers and 55% reported a frequency of alcohol consumption higher than once a week. Many (69%) had never fathered a pregnancy, and few reported potential occupational hazards (25%) or histories of certain diseases (20%).

###### 

Subject demographics and semen parameters ($n = 664$).

Table 1 lists characteristics in the first column; the corresponding values for mean plus or minus SD, median, and n percentage are listed in the other columns.

  Characteristic[^*a*^](#TF2){ref-type="table-fn"}           $\text{Mean} \pm \text{SD}$   Median (5th, 95th)   $n$ (%)
  ---------------------------------------------------------- ----------------------------- -------------------- ------------
  Age (y)                                                    $29.4 \pm 5.4$                29.0 (21.0, 39.0)    
  BMI (${{kg}/m}^{2}$)                                       $23.9 \pm 3.1$                23.9 (19.0, 29.4)    
  Abstinence (d)                                             $4.8 \pm 2.2$                 4.0 (2.0, 10.0)      
  Smoking status during last 3 months                                                                           
   No smoking                                                                              357 (53.8)           
   $< 1\text{ \ cigarette}/d$                                                              46 (6.9)             
   1--9 cigarettes/d                                                                       80 (12.0)            
   10--19 cigarettes/d                                                                     121 (18.2)           
   $\geq 20\text{ \ cigarettes}/d$                                                         60 (9.0)             
  Alcohol consumption during last 3 months                                                                      
   $< 1$ alcoholic beverage/week                                                           299 (45.0)           
   $\geq 1$ alcoholic beverage/week                                                        365 (55.0)           
  Occupation[^*b*^](#TF3){ref-type="table-fn"}                                                                  
   Potential occupational hazard                                                                                163 (24.5)
   No hazard                                                                                                    501 (75.5)
  Medical history                                                                                               
   Self-reported disease[^*c*^](#TF4){ref-type="table-fn"}                                                      133 (20.0)
   Not reported                                                                                                 531 (80.0)
  Reproductive history                                                                                          
   Fathered a pregnancy                                                                                         203 (30.6)
   Never fathered a pregnancy                                                                                   461 (69.4)
  Semen volume (mL)                                          $4.0 \pm 1.5$                 3.7 (2.2, 6.9)       
  Sperm concentration (million/mL)                           $51.6 \pm 46.9$               38.1 (4.3, 150)      
  Total sperm count (million)                                $196 \pm 178$                 146 (15.6, 573)      
  Progressive motile (%)                                     $32.3 \pm 13.9$               31.8 (10.7, 56.5)    
  Curvilinear velocity ($\mu m/s$)                           $32.2 \pm 8.0$                31.8 (20.1, 45.1)    
  Straight-line velocity ($\mu m/s$)                         $22.8 \pm 6.6$                22.8 (11.6, 33.1)    
  Morphologically normal (%)                                 $4.8 \pm 2.1$                 4.8 (1.4, 8.1)       
  DNA fragmentation index (%)                                $18.9 \pm 12.1$               15.8 (4.8, 44.8)     
  High DNA stainability (%)                                  $9.9 \pm 4.8$                 8.9 (4.5, 18.4)      

Note: BMI, body mass index; SD, standard deviation.

Data were complete for all variables shown in the table.

Question was "Does your current job involve any of the following? ---Heavy exertion, extreme heat, or chemical exposure." combined into one variable (yes/no). Numbers reporting heavy exertion, extreme heat, and chemical exposure were 134, 30, and 19, respectively.

Included hyperlipidemia, hypertension, hyperglycemia, coronary artery disease, fatty liver disease, renal calculus, hepatitis, psoriasis, hyperthyroidism and/or parotitis, combined into one variable (reported or not reported).

PFAS Profiles in Serum and Semen {#s3.2}
--------------------------------

[Table 2](#t2){ref-type="table"} shows the distribution of detected PFASs in serum--semen paired samples. PFBA, PFPeA, and PFHxA were not detected in any samples, and hence were not considered any further. Most other target analytes were readily detected in serum ($\text{detection\  \ rate} > 90\%$), except for PFHpA, PFTeDA, and PFBS, for which only 24%, 37%, and 80% of tested samples were found to be above the LOQs, respectively. In serum samples, PFOA (median: $8.57\text{ \ ng}/{mL}$), PFOS ($8.38\text{ \ ng}/{mL}$), and 6:2 Cl-PFESA ($6.09\text{ \ ng}/{mL}$) were the three most dominant compounds, accounting for approximately $84 \pm 4.9\%$ of total PFASs. The scatter plots show moderate-to-high correlations between individual PFAS levels in the two matrices ($\text{Pearson\  \ correlation\  \ coefficients} = 0.58–0.83$, $p < 0.001$; [Figure 1](#f1){ref-type="fig"}). Significant correlations were also observed among those PFASs in serum and in semen ($R = 0.28–0.91$; see Tables S3 and S4). Compared with those in serum samples, the detection rates and concentrations of PFASs decreased sharply in the corresponding semen samples. The detection rate reached 100% for PFOA and 6:2 Cl-PFESA, and ranged from 77% to 96% for PFOS, PFNA, PFDA, PFUnDA, and PFTriDA. Other PFASs were also found at quantifiable levels in a few samples (2.7--31%) ([Table 2](#t2){ref-type="table"}). The observed concentration sequence ($\text{PFOA} > \text{PFOS} > 6:2\text{ \ Cl-PFESA} \geq \text{PFNA} > \text{PFDA} > \text{PFUnDA} \geq \text{other\  \ PFASs}$) was identical to that in serum, but at concentrations tens to hundreds of times lower (Wilcoxon rank sum test, $p < 0.001$ for each PFAS). The percentage contribution of PFOA increased significantly from 32% in serum to 50% in semen (Wilcoxon rank sum test, $p < 0.001$), whereas the proportion of PFOS and 6:2 Cl-PFESA decreased from 30% and 22% in serum to 20% and 14% in semen, respectively ($p < 0.001$).

###### 

Concentrations (ng/mL) of PFASs in paired serum and semen samples ($n = 664$).

Table 2 lists PFAS in the first column; the corresponding detection rate, minimum values, 25th percentile, 50th percentile, 75th percentile, maximum values, and percentage of proportion are listed in the other columns.

  PFAS           DR (%)   Min              25th             50th             75th             Max     Proportion (%)[^*a*^](#TF6){ref-type="table-fn"}
  -------------- -------- ---------------- ---------------- ---------------- ---------------- ------- --------------------------------------------------
  Serum                                                                                               
  PFHpA          23.6     $< \text{LOQ}$   $< \text{LOQ}$   $< \text{LOQ}$   $< \text{LOQ}$   0.509   0.1
  PFOA           100      1.660            6.804            8.567            11.04            95.69   32.1
  PFNA           100      0.274            1.011            1.466            2.216            17.30   5.3
  PFDA           99.8     0.014            0.706            1.240            2.031            20.24   4.6
  PFUnDA         100      0.049            0.453            0.747            1.198            7.788   2.7
  PFDoDA         93.8     $< \text{LOQ}$   0.042            0.074            0.121            0.857   0.3
  PFTriDA        99.1     $< \text{LOQ}$   0.074            0.124            0.200            0.929   0.4
  PFTeDA         37.0     $< \text{LOQ}$   $< \text{LOQ}$   $< \text{LOQ}$   0.021            0.115   0.0
  PFBS           80.3     $< \text{LOQ}$   0.017            0.033            0.053            1.054   0.2
  PFHxS          100      0.081            0.460            0.664            0.932            10.12   2.7
  PFOS           100      1.256            5.568            8.378            13.09            337.0   29.7
  6:2 Cl-PFESA   100      0.441            3.356            6.088            9.895            96.06   21.7
  8:2 Cl-PFESA   96.5     $< \text{LOQ}$   0.043            0.081            0.153            3.769   0.4
  Semen                                                                                               
  PFHpA          2.7      $< \text{LOQ}$   $< \text{LOQ}$   $< \text{LOQ}$   $< \text{LOQ}$   0.060   0.1
  PFOA           100      0.043            0.153            0.229            0.362            2.966   49.6
  PFNA           83.9     $< \text{LOQ}$   0.013            0.024            0.042            0.360   4.4
  PFDA           83.4     $< \text{LOQ}$   0.012            0.020            0.034            0.250   3.8
  PFUnDA         83.9     $< \text{LOQ}$   0.009            0.016            0.028            0.214   3.2
  PFDoDA         29.5     $< \text{LOQ}$   $< \text{LOQ}$   $< \text{LOQ}$   0.005            0.062   0.3
  PFTriDA        76.5     $< \text{LOQ}$   0.004            0.008            0.013            0.090   1.7
  PFTeDA         14.2     $< \text{LOQ}$   $< \text{LOQ}$   $< \text{LOQ}$   $< \text{LOQ}$   0.060   0.1
  PFBS           6.2      $< \text{LOQ}$   $< \text{LOQ}$   $< \text{LOQ}$   $< \text{LOQ}$   0.094   0.1
  PFHxS          30.7     $< \text{LOQ}$   $< \text{LOQ}$   $< \text{LOQ}$   0.021            0.246   1.7
  PFOS           96.1     $< \text{LOQ}$   0.055            0.097            0.179            8.716   20.4
  6:2 Cl-PFESA   100      0.005            0.035            0.064            0.119            1.368   14.3
  8:2 Cl-PFESA   30.6     $< \text{LOQ}$   $< \text{LOQ}$   $< \text{LOQ}$   0.004            0.077   0.3

Note: Cl-PFESA, chlorinated polyfluorinated ether sulfonate; DR, detection rate; LOQ, limit of quantitation; Max, maximum; Min, minimum; PFAS, per-/polyfluoroalkyl substance; PFBS, perfluorobutane sulfonate; PFDA, perfluorodecanoate; PFDoDA, perfluorododecanoate; PFHpA, perfluoroheptanoate; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoate; PFOA, perfluorooctanoate; PFOS, perfluorooctane sulfonate; PFTeDA, perfluorotetradecanoate; PFTriDA, perfluorotridecanoate; PFUnDA, perfluoroundecanoate.

Average proportion among all PFASs in the considered matrix (semen or serum).

![Concentrations of PFASs (ng/mL) in semen versus serum ($n = 664$). All samples were included in the plot. Censored likelihood multiple imputation was used to impute PFAS concentrations below the LOQ. Note: Cl-PFESA, chlorinated polyfluorinated ether sulfonate; LOQ, limit of quantitation; PFAS, per-/polyfluoroalkyl substance; PFDA, perfluorodecanoate; PFDoDA, perfluorododecanoate; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoate; PFOA, perfluorooctanoate; PFOS, perfluorooctane sulfonate; PFTriDA, perfluorotridecanoate; PFUnDA, perfluoroundecanoate.](ehp-127-127005-g001){#f1}

Percentage ratios of individual PFASs in semen versus those in serum were calculated as a hypothetical indicator of PFAS transfer efficiency into the reproductive system from the whole body ([Figure 2](#f2){ref-type="fig"}). The concentration ratios showed a descending trend with increasing perfluorinated carbon number from PFOA (C7) to PFNA (C8); and then increased from PFNA (C8) to PFTriDA (C13), with a U-shaped trend observed for perfluoroalkyl carboxylic acids. A similar U-shaped trend was also observed for per- and polyfluoroalkyl sulfonic acids; the ratio reached the lowest level when sulfonic acids contained eight perfluorinated carbons (i.e., PFOS and 6:2 Cl-PFESA) and increased with increasing or decreasing carbon number ([Figure 2](#f2){ref-type="fig"}). The pattern in concentration ratios was similar after excluding all values with imputation, that is to say, including only paired serum--semen samples with PFAS levels greater than the LOQs in the analysis (see Table S5).

![Percentage ratios of PFAS levels (semen vs. serum) with increasing perfluorinated carbon number ($n = 664$; see Table S5 for corresponding numerical data). Dots correspond to estimated mean values; whiskers indicate 95% confidence intervals. Perfluoroalkyl carboxylic acids and sulfonic acids are separated on the left and right, respectively. Censored likelihood multiple imputation was used to impute PFAS concentrations below the LOQ. Note: Cl-PFESA, chlorinated polyfluorinated ether sulfonate; LOQ, limit of quantitation; PFAS, per-/polyfluoroalkyl substance; PFDA, perfluorodecanoate; PFDoDA, perfluorododecanoate; PFHxS, perfluorohexane sulfonate; PFOA, perfluorooctanoate; PFOS, perfluorooctane sulfonate; PFTriDA, perfluorotridecanoate; PFUnDA, perfluoroundecanoate.](ehp-127-127005-g002){#f2}

PFAS Concentration and Semen Quality {#s3.3}
------------------------------------

[Table 3](#t3){ref-type="table"} shows the associations between semen quality parameters and seminal concentrations of PFASs detected at frequencies above 80% (i.e., PFOA, PFNA, PFDA, PFUnDA, PFOS, and 6:2 Cl-PFESA). The associations in the paired serum samples are provided in [Table 4](#t4){ref-type="table"}. Concerning seminal PFASs, two semen quality end points were associated with various PFASs: *a*) reduction in the percentage of progressive sperm (PFOA, PFNA, PFUnDA, PFOS, and 6:2 Cl-PFESA); and *b*) increase in the percentage of DNA fragmentation (PFOA, PFNA, PFDA, PFOS, and 6:2 Cl-PFESA). Other semen parameters were significantly associated with individual PFASs, most often with PFOA and PFOS. A 1-unit increase in ln-transformed PFOA was associated with cubic-root sperm concentration \[$\beta = 0.193$; 95% confidence interval (CI): 0.075, 0.311\] and cubic-root total sperm count ($\beta = 0.247$; 95% CI: 0.061, 0.432); PFOS was associated with lower VSL ($\beta = –0.773$; 95% CI: $–1.337$, $–0.209$). For serum PFASs, significant results were only observed for the percentage of sperm with high DNA stainability. Higher DNA stainability was consistently associated with higher serum PFNA ($\beta = 0.119$; 95% CI: 0.063, 0.176), PFDA ($\beta = 0.073$; 95% CI: 0.031, 0.115), PFUnDA ($\beta = 0.106$; 95% CI: 0.060, 0.152), and 6:2 Cl-PFESA ($\beta = 0.076$; 95% CI: 0.037, 0.115). The associations with PFDA, PFUnDA, and 6:2 Cl-PFESA were consistent with those observed for semen PFAS levels, but less so for PFNA. In sensitivity analyses, the magnitudes of the estimates and *p*-values were essentially unchanged after adjustment for both semen and serum PFASs (see Table S6). Most of the abovementioned associations remained statistically significant, except for the associations with DNA stainability, which became weaker for both semen and serum PFASs (statistical significance was only reached for serum PFNA). Although the *p*-values increased, a positive association with HDS was still observed for serum PFASs, but basically became null for semen PFASs.

###### 

Estimated changes in semen quality parameters associated with a 1-unit increase in ln-transformed PFAS levels in semen ($n = 664$).

Table 3 lists outcomes in the first column; the corresponding values for PFOA, PFNA, PFDA, PFUnDA, PFOS, and 6:2 CI PFESA are listed in the other columns.

  Outcome[^*a*^](#TF8){ref-type="table-fn"}                    PFOA                            *p*-Value   PFNA                            *p*-Value   PFDA                            *p*-Value   PFUnDA                          *p*-Value   PFOS                            *p*-Value   6:2 Cl-PFESA                    *p*-Value
  ------------------------------------------------------------ ------------------------------- ----------- ------------------------------- ----------- ------------------------------- ----------- ------------------------------- ----------- ------------------------------- ----------- ------------------------------- -----------
  Semen volume (mL) [^*b*^](#TF9){ref-type="table-fn"}         $–0.025$ ($–0.066$, 0.016)      0.4         $–0.020$ ($–0.053$, 0.013)      0.4         $–0.012$ ($–0.046$, 0.023)      0.7         $–0.034$ ($–0.065$, $–0.003$)   0.1         $–0.007$ ($–0.038$, 0.024)      0.8         $–0.001$ ($–0.031$, 0.030)      1.0
  Sperm conc. (million/mL)[^*b*^](#TF9){ref-type="table-fn"}   0.193 (0.075, 0.311)            0.02        0.090 ($–0.008$, 0.188)         0.2         0.046 ($–0.058$, 0.150)         0.5         0.092 (0.002, 0.182)            0.1         0.098 (0.008, 0.188)            0.1         0.069 ($–0.019$, 0.158)         0.3
  Sperm count (million)[^*b*^](#TF9){ref-type="table-fn"}      0.247 (0.061, 0.432)            0.05        0.101 ($–0.053$, 0.254)         0.4         0.048 ($–0.113$, 0.209)         0.7         0.081 ($–0.059$, 0.222)         0.4         0.133 ($–0.008$, 0.274)         0.2         0.104 ($–0.035$, 0.242)         0.3
  Progressive motile (%)                                       $–2.377$ ($–3.940$, $–0.815$)   0.03        $–1.999$ ($–3.284$, $–0.714$)   0.02        $–1.475$ ($–2.796$, $–0.155$)   0.1         $–1.667$ ($–2.860$, $–0.474$)   0.04        $–1.700$ ($–2.867$, $–0.532$)   0.03        $–1.618$ ($–2.787$, $–0.449$)   0.04
  VCL ($\mu m/s$)                                              $–1.155$ ($–2.064$, $–0.245$)   0.06        $–0.792$ ($–1.542$, $–0.042$)   0.1         $–0.547$ ($–1.325$, 0.231)      0.3         $–0.470$ ($–1.159$, 0.218)      0.4         $–0.767$ ($–1.447$, $–0.087$)   0.1         $–0.593$ ($–1.274$, 0.089)      0.2
  VSL ($\mu m/s$)                                              $–0.920$ ($–1.676$, $–0.165$)   0.08        $–0.686$ ($–1.315$, $–0.058$)   0.1         $–0.659$ ($–1.305$, $–0.013$)   0.1         $–0.691$ ($–1.264$, $–0.119$)   0.08        $–0.773$ ($–1.337$, $–0.209$)   0.04        $–0.647$ ($–1.212$, $–0.082$)   0.1
  Morphologically normal (%)                                   $–0.117$ ($–0.361$, 0.127)      0.5         $–0.146$ ($–0.344$, 0.051)      0.3         $–0.168$ ($–0.376$, 0.040)      0.3         $–0.128$ ($–0.313$, 0.057)      0.3         0.004 ($–0.179$, 0.187)         1.0         $–0.023$ ($–0.206$, 0.159)      0.9
  DFI (%)                                                      0.136 (0.064, 0.209)            0.01        0.106 (0.047, 0.165)            0.01        0.083 (0.021, 0.145)            0.05        0.048 ($–0.008$, 0.103)         0.2         0.087 (0.033, 0.142)            0.02        0.080 (0.026, 0.135)            0.03
  HDS (%)                                                      0.035 ($–0.015$, 0.084)         0.3         0.044 (0.002, 0.086)            0.1         0.068 (0.026, 0.110)            0.02        0.069 (0.030, 0.107)            0.01        0.033 ($–0.004$, 0.070)         0.2         0.054 (0.017, 0.090)            0.03

Note: Estimates calculated using linear regression models adjusted for age, BMI, $\text{BMI}^{2}$, smoking, alcohol intake, and abstinence time. Censored likelihood multiple imputation was used when PFAS levels were below LOQ. *p*-Values were false discovery rate (FDR)-adjusted to reduce overall testing error rate. BMI, body mass index; CI, confidence interval; Cl-PFESA, chlorinated polyfluorinated ether sulfonate; conc., concentration; DFI, DNA fragmentation index; HDS, high DNA stainability; LOQ, limit of quantitation; PFAS, per-/polyfluoroalkyl substance; PFDA, perfluorodecanoate; PFNA, perfluorononanoate; PFOA, perfluorooctanoate; PFOS, perfluorooctane sulfonate; PFUnDA, perfluoroundecanoate; VCL, curvilinear velocity; VSL, straight-line velocity.

Semen volume, DFI, and HDS were ln transformed, sperm concentration and total sperm count were cubic-root transformed, other parameters were not transformed.

Subjects reporting spillage during semen collection ($n = 21$) were excluded from these analyses.

###### 

Estimated changes in semen quality parameters associated with a 1-unit increase in ln-transformed PFAS levels in serum ($n = 664$).

Table 4 lists outcomes in the first column; the corresponding values for PFOA, PFNA, PFDA, PFUnDA, PFOS, and 6:2 CI PFESA are listed in the other columns.

  Outcome[^*a*^](#TF11){ref-type="table-fn"}                    PFOA                         *p*-Value   PFNA                         *p*-Value   PFDA                         *p*-Value   PFUnDA                       *p*-Value   PFOS                         *p*-Value   6:2 Cl-PFESA                 *p*-Value
  ------------------------------------------------------------- ---------------------------- ----------- ---------------------------- ----------- ---------------------------- ----------- ---------------------------- ----------- ---------------------------- ----------- ---------------------------- -----------
  Semen volume (mL)[^*b*^](#TF12){ref-type="table-fn"}          0.048 ($–0.006$, 0.103)      0.2         0.031 ($–0.016$, 0.078)      0.4         0.033 ($–0.001$, 0.068)      0.2         0.022 ($–0.016$, 0.060)      0.4         0.042 ($–0.002$, 0.085)      0.2         0.044 (0.011, 0.076)         0.06
  Sperm conc. (million/mL)[^*b*^](#TF12){ref-type="table-fn"}   0.083 ($–0.075$, 0.242)      0.5         $–0.060$ ($–0.197$, 0.077)   0.5         $–0.065$ ($–0.166$, 0.035)   0.4         $–0.062$ ($–0.173$, 0.048)   0.4         $–0.004$ ($–0.131$, 0.124)   1.0         $–0.059$ ($–0.153$, 0.034)   0.4
  Sperm count (million)[^*b*^](#TF12){ref-type="table-fn"}      0.209 ($–0.039$, 0.457)      0.2         $–0.043$ ($–0.258$, 0.171)   0.8         $–0.049$ ($–0.206$, 0.109)   0.7         $–0.056$ ($–0.230$, 0.118)   0.7         0.061 ($–0.139$, 0.262)      0.7         $–0.014$ ($–0.161$, 0.134)   1.0
  Progressive motile (%)                                        $–0.890$ ($–2.997$, 1.217)   0.6         0.040 ($–1.782$, 1.862)      1.0         0.861 ($–0.478$, 2.200)      0.4         0.568 ($–0.905$, 2.041)      0.6         $–0.095$ ($–1.746$, 1.557)   1.0         0.068 ($–1.188$, 1.323)      1.0
  VCL ($\mu m/s$)                                               0.280 ($–0.944$, 1.504)      0.8         0.272 ($–0.786$, 1.330)      0.7         0.764 ($–0.013$, 1.540)      0.2         0.492 ($–0.363$, 1.347)      0.4         0.278 ($–0.681$, 1.237)      0.7         0.475 ($–0.253$, 1.203)      0.4
  VSL ($\mu m/s$)                                               $–0.054$ ($–1.070$, 0.963)   1.0         $–0.053$ ($–0.931$, 0.826)   1.0         0.317 ($–0.329$, 0.963)      0.5         0.062 ($–0.649$, 0.773)      1.0         $–0.035$ ($–0.832$, 0.762)   1.0         0.190 ($–0.415$, 0.795)      0.7
  Morphologically normal (%)                                    $–0.162$ ($–0.490$, 0.165)   0.5         $–0.262$ ($–0.545$, 0.020)   0.2         $–0.090$ ($–0.298$, 0.118)   0.5         $–0.176$ ($–0.405$, 0.052)   0.3         $–0.067$ ($–0.324$, 0.189)   0.7         $–0.061$ ($–0.256$, 0.133)   0.7
  DFI (%)                                                       0.046 ($–0.052$, 0.144)      0.5         $–0.004$ ($–0.089$, 0.081)   1.0         $–0.034$ ($–0.097$, 0.028)   0.4         $–0.033$ ($–0.102$, 0.035)   0.5         0.040 ($–0.037$, 0.116)      0.5         0.012 ($–0.046$, 0.071)      0.8
  HDS (%)                                                       0.061 ($–0.005$, 0.127)      0.2         0.119 (0.063, 0.176)         0.01        0.073 (0.031, 0.115)         0.02        0.106 (0.060, 0.152)         0.01        0.059 (0.007, 0.111)         0.1         0.076 (0.037, 0.115)         0.01

Note: Estimates calculated using linear regression models adjusted for age, BMI, $\text{BMI}^{2}$, smoking, alcohol intake, and abstinence time. *p*-Values were false discovery rate (FDR)-adjusted to reduce overall testing error rate. BMI, body mass index; CI, confidence interval; Cl-PFESA, chlorinated polyfluorinated ether sulfonate; conc., concentration; DFI, DNA fragmentation index; HDS, high DNA stainability; PFAS, per-/polyfluoroalkyl substance; PFDA, perfluorodecanoate; PFNA, perfluorononanoate; PFOA, perfluorooctanoate; PFOS, perfluorooctane sulfonate; PFUnDA, perfluoroundecanoate; VCL, curvilinear velocity; VSL, straight-line velocity.

Semen volume, DFI, and HDS were ln transformed, sperm concentration and total sperm count were cubic-root transformed, other parameters were not transformed.

Subjects reporting spillage during semen collection ($n = 21$) were excluded from these analyses.

[Figure 3](#f3){ref-type="fig"} presents the associations of selected outcomes with semen and serum PFAS concentrations across quartiles. The corresponding results for the other outcomes are shown in Figure S1. In accordance with the significant associations from the continuous models, a 2.9--5.5% decline in the percentage of progressive sperm and 0.16--0.25% increase in the per log unit percentage of DNA fragmentation were observed in the highest quartile of seminal PFASs versus the lowest ([Figure 3](#f3){ref-type="fig"}). No significant differences or clear patterns were observed in the serum PFAS quartiles for sperm motility or DNA fragmentation. However, for the percentage of sperm with high DNA stainability, the positive trends across PFAS quartiles in serum tended to be clearer than those in semen. A 0.08--0.18% increase in the per log unit HDS was observed in the highest quartile of serum PFASs versus the lowest and was 1.1--2.0 times greater than the corresponding increment in the highest quartile of semen PFASs compared with the lowest ([Figure 3](#f3){ref-type="fig"}). No clear patterns were observed for other sperm parameters in semen or serum PFAS quartiles (see Figure S1).

![Regression coefficients and 95% confidence intervals for changes in selected semen parameters across PFAS quartiles ($n = 664$; see Tables S7 and S8 for corresponding numerical data). First quartile (Q1) was used as a reference group. Concentration ranges for PFASs across quartiles are listed in [Table 2](#t2){ref-type="table"}. Models were adjusted for age, BMI, $\text{BMI}^{2}$, smoking, alcohol intake, and abstinence time. DNA fragmentation index (DFI) and high DNA stainability (HDS) were ln-transformed. FDR-adjusted *p*-values were used for trends and are shown in blue (semen) and black (serum PFAS quartiles). Note: BMI, body mass index; Cl-PFESA, chlorinated polyfluorinated ether sulfonate; FDR, false discovery rate; PFAS, per-/polyfluoroalkyl substance; PFDA, perfluorodecanoate; PFNA, perfluorononanoate; PFOA, perfluorooctanoate; PFOS, perfluorooctane sulfonate; PFUnDA, perfluoroundecanoate; Q, quartile.](ehp-127-127005-g003){#f3}

Discussion {#s4}
==========

In the paired semen and serum samples, concentrations of seminal PFASs were two to three orders of magnitude lower but were strongly correlated with those in serum. A U-shaped trend was observed for the concentration ratios (semen vs. serum) of carboxylic and sulfonic acids with increasing chain length, suggesting a possible structure-dependent partitioning of PFASs between the two matrices. Compared with those in serum, seminal PFAS levels were more clearly associated with semen quality parameters in this cross-sectional study of 664 Chinese adults, except for DNA stainability. Sperm motility and DFI were the two outcomes most consistently associated with seminal PFAS levels, with HDS also significantly associated with some PFASs in both semen and serum.

The high detection and abundance of PFASs in serum indicated that PFAS exposure is still widespread and relatively high in Chinese men, even after worldwide regulations on PFOS and PFOA production ([@c29]). China has banned the production and usage of PFOS (with specific exemptions) since 2014 ([@c32]). A grant from the Global Environment Facility was approved in 2017 to support the reduction of PFOS in China ([@c59]). PFOA has also been listed as a "product with high pollution and high environmental risk" by the Chinese government ([@c33]), although no administrative restriction on its production and usage has yet been promulgated. Serum levels of legacy PFASs, particularly PFOA, were 3- to 11-fold higher in the present population (median $8.57\text{ \ ng}/{mL}$; sampling year: 2015--2016) than in general populations from other countries: for example, the United States ($1.94\text{ \ ng}/{mL}$; 2013--2014; [@c13]), South Korea ($3.22\text{ \ ng}/{mL}$; 2009--2010; [@c28]), Japan ($2.1\text{ \ ng}/{mL}$; 2009--2010; [@c61]), Spain ($1.99\text{ \ ng}/{mL}$; 2007--2009; [@c5]), Czech Republic ($0.76\text{ \ ng}/{mL}$; 2015; [@c49]), Sweden ($2.25\text{ \ ng}/{mL}$; 2010--2011; [@c7]), and Norway ($1.92\text{ \ ng}/{mL}$; 2010--2011; [@c3]). Aside from exposure to legacy PFASs, 6:2 Cl-PFESA (commercially F-53B), a replacement chemical for PFOS in the Chinese plating industry ([@c55]), has become an emerging concern. Similar to previous investigations on pregnant mothers and fetuses in China ([@c38]), serum concentrations of 6:2 Cl-PFESA (median $6.09\text{ \ ng}/{mL}$) were the third highest among all detected PFASs and accounted for a 2-fold larger proportion (22%) in men than that reported in pregnant women and fetuses ($\sim 10\%$; [@c38]). To the best of our knowledge, this is the first study to report on baseline levels of 6:2 Cl-PFESA among Chinese male adults and the first to explore its epidemiological association with semen quality. With such comparable concentrations of PFOS in Chinese populations, concerning on toxicity and epidemiological effect of 6:2 Cl-PFESA should not be neglected.

Albeit at levels much lower than those in serum, the widespread presence of the six dominant PFASs (i.e., PFOA, PFOS, 6:2 Cl-PFESA, PFNA, PFDA, and PFUnDA) in semen reflects exposure. Therefore, the next step was to establish correlations between levels in semen and serum to ensure that seminal PFAS levels can be related to actual body burden. Our results demonstrated that concentrations of the six major PFASs among the two matrices were highly correlated ([Figure 1](#f1){ref-type="fig"}). Several studies have reported on the transfer ratios of chemicals from serum (or blood) to semen. Although semen levels can be tens \[e.g., lead ([@c2]; [@c52])\] to thousands \[e.g., dioxins ([@c45])\] of times lower than levels in serum or blood, they can also be at comparable \[e.g., cadmium ([@c52]); parabens ([@c16])\] or higher concentrations \[e.g., zinc ([@c52]; [@c60])\]. These discrepancies in concentration ratios indicate different transfer efficiencies and mechanisms for the different chemicals transferring into semen. As for PFASs, we assessed their transfer ratios from serum to semen for the first time and found preliminary evidence that efficiencies for PFASs entering semen may be related to perfluorinated carbon chain length and functional group ([Figure 2](#f2){ref-type="fig"}). However, the observed pattern was driven by PFASs with a large proportion of samples below the LOQ (i.e., PFDoDA, PFTriDA, PFHxS, and 8:2 Cl-PFESA) and thus needs to be interpreted with caution until confirmed in a larger study. Given that PFASs are highly protein-bound in serum ([@c24]), their binding affinity to serum proteins likely plays a critical role in their transfer efficiency. Those PFASs with greater affinities will bind to serum proteins and consequently limit the bioavailability of the molecule ([@c65]), whereas those PFASs with lower binding affinities to protein will be more easily released from serum and transferred to other matrices, such as semen. The binding capacities to albumin, the most abundant protein in serum, have been shown to increase for C2--C8 PFCAs but to decrease for C9--C12 PFCAs ([@c6]). A similar pattern has also been observed for C7--C16 PFCAs binding to fatty acid binding protein (FABP), another major serum protein ([@c64]). This evidence may partially explain the suggestive U-shaped trend found for PFAS transfer ratios in the present study; however, further investigation is needed to verify the influence from serum proteins and to explore other factors affecting the transmission of PFASs into semen.

Semen consists of a concentrated suspension of spermatozoa stored in epididymides and fluid secretions from accessory sex organs, including seminal vesicles, prostate, bulbourethral glands, and epididymides ([@c58]). Although it is not a direct measure of levels in sex organs (impractical for human studies), levels in semen can, to some extent, represent the levels of PFASs infiltrating the overall reproductive system, which may be a fraction of the active PFASs affecting reproductive function. Thus, seminal PFAS levels are a more direct marker than serum PFASs, given that individual differences (e.g., serum protein levels) can lead to discrepancies in levels of PFASs entering the reproductive system, despite study subjects experiencing the same serum PFAS exposure. This may explain the clearer association of seminal than serum PFAS levels with semen quality. However, it should be noted that there is greater potential for confounding by physiological conditions when PFAS exposure is assessed in semen than in serum. This is because the closer exposure and outcome are physiologically (e.g., assessed in the same organ), the greater the extraneous factors and hence potential confounders ([@c57]). For instance, if a certain condition in the prostate or testis (not influenced by PFAS) can alter both semen volume and other semen parameters, this could induce an indirect association between seminal PFASs (because an effect on semen volume may influence PFAS concentration) and other semen parameters. The potential for this to occur with serum PFAS concentrations is weaker because a condition in the prostate or testis would be less likely to influence serum PFAS levels than semen PFAS levels. The possibility of potential confounding cannot be ruled out in the present study and warrants further exploration.

Our study showed significant associations between higher seminal PFAS levels and decreased progressive sperm ([Table 3](#t3){ref-type="table"}). The result corroborated earlier findings that PFAS exposure may be correlated with diminished sperm motility, although the PFAS exposure burden in our study population was much lower (e.g., median PFOS level in serum: 8.4 vs. $96\text{ \ ng}/{mL}$; [@c50]). The present study also provided positive evidence on previously obscure associations between PFASs and sperm DNA fragmentation. Only a marginally significant increase in DNA fragmentation was reported with increasing serum PFOA levels in one subgroup from the Biopersistent organochlorines in diet and human fertility: Epidemiologic studies of time to pregnancy and semen quality in Inuit and European populations (INUENDO) cohort ([@c51]), whereas no significant change in DFI with any serum PFAS levels was found in the Longitudinal Investigation of Fertility and the Environment (LIFE) Study ([@c9]). Here, seminal levels of PFOA, PFNA, PFDA, PFOS, and 6:2 Cl-PFESA were consistently associated with an increased percentage of DNA fragmentation; however, our results did not fully contradict previous studies given that we did not observe any clear patterns between serum PFASs and DFI. Another noteworthy finding was the positive association between PFASs in both serum and semen and the percentage of high DNA stainability, a marker of sperm chromatin immaturity. Only one previous study has focused on this outcome, pointing to a negative association between percentage of DNA stainability and increased perfluorooctane sulfonamide (PFOSA) and 2-(*N*-methyl-perfluorooctane sulfonamido) acetate (Me-PFOSA-AcOH) levels in serum ([@c9]). However, neither of these compounds were included in our analysis, which hampers a more complete comparison between the two studies.

Nonetheless, our findings are supported by previous toxicological evidence. It has been shown that PFAS exposure *in vitro* induces obvious detachment of primary gonocytes from Sertoli cells ([@c63]), which can lead to a higher proportion of immature sperm. This concept supports the higher HDS association we observed in the current study. In addition, animal studies have reported excessive production of reactive oxygen species in the reproductive system induced by PFAS exposure ([@c19]; [@c30]). This can, in turn, lead to an increase in oxidative stress and consequent DNA damage ([@c1]) and mitochondrial dysfunction ([@c10]) during spermatogenesis, which is in accord with the increased DFI and decreased sperm motility observed in the present study. However, some phenomena cannot be explained. In contrast to our hypothesis and finding that semen quality parameters were more significantly associated with PFASs in semen than those in serum, HDS appeared to be more clearly associated with serum PFAS levels. Although PFOA and PFOS were most frequently associated with other semen quality end points, HDS tended to be associated with larger molecule PFASs (i.e., PFNA, PFDA, PFUnDA, and 6:2 Cl-PFESA), and not with PFOA and PFOS. There might be other underlying mechanisms (perhaps not a direct testicular effect) acting upon HDS, and future exploration is still needed. Seminal PFOA levels were unexpectedly associated with higher sperm concentration, although it is unlikely that this suggests a protective effect on spermatogenesis. The linear trend across the PFOA quartile was not statistically significant (see Figure S1); nor were other PFASs significantly associated with sperm concentration. The possibility of a chance finding or uncontrolled confounding effect cannot be ruled out.

The strengths of the present study include the simultaneous collection of paired semen and serum samples and large sample size (664 men). Thus, this study improves our understanding on PFAS partitioning between semen and serum and provides affirmative evidence on the deleterious effects of PFASs on human semen quality. Our results were further strengthened by the correction of multiple comparisons, with FDR-based adjustments conducted to reduce the possibility of chance findings.

However, the following study limitations should also be considered. First, as is the case for most studies focusing on PFASs and semen quality, the temporal relationships between exposure and outcome could not be ascertained based on the cross-sectional design of the research. To corroborate our findings, longitudinal study with repeated measurements of PFAS concentrations and semen quality over time is needed, as well as further exploration on whether any mediators caused or influenced the observed relationships between seminal PFAS levels and semen quality. Second, the study population was recruited from an infertility clinic and, although we excluded those with severe reproductive diseases, the subjects could be considered subfertile and may not be representative of the general population. Third, reproductive hormone measurements are absent from the present study, which hampers exploration on the role of hormones in affecting semen quality. Previous studies have indicated a negative relationship between serum PFASs and testosterone ([@c22], [@c23]). Based on the fact that testosterone is synthesized in the testes, and our hypothesis that seminal PFAS levels may more directly represent the actual burden to the reproductive system than serum PFAS levels, it would be interesting to determine if there was a clearer association of seminal PFAS levels than serum PFAS levels with serum testosterone.

Conclusions {#s5}
===========

Based on a cross-sectional study of 664 Chinese men, we found various semen quality parameters to be significantly associated with seminal PFAS levels. The associations with PFAS levels in the matched serum were rarely significant. Our results suggest that PFASs may have deleterious effects on human semen quality at environmentally relevant concentrations. Furthermore, clearer associations of semen quality with seminal PFASs compared with serum PFASs suggest that measuring exposures in the target tissue may be important to clarify effects. Based on the measurement of seminal PFAS levels, this study provides affirmative evidence on previously equivocal results regarding whether PFASs impair human semen quality and highlights that seminal PFASs, albeit at trace levels, may be a more direct exposure marker than serum PFAS levels for epidemiological studies on male reproductive function.
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